• About
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • iNKT Cells
    • ARDS & Infectious Diseases
    • Cancer
    • GvHD
    • Publications
  • Platform
    • Manufacturing
    • Engineering
  • Pipeline
  • Investor & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Financials & Filings
    • Corporate Governance
  • Careers
  • Contact
  • Home
  • Publications

Publications

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2020

AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing, B. Yigit, et al.

Poster •November 11 - 14, 2020

SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2019

Discovery and characterization of the first fully-human Phosphopeptide Tumor Target-specific T cell receptor, X. Michelet, et al.

Poster •November 7 - 10, 2019

Invariant natural killer T cells as an allogeneic cell therapy platform, B. Yigit, et al.

Poster •November 7 - 10, 2019

MiNK

MiNK Therapeutics, Inc.

149 Fifth Avenue
Suite 500
New York, NY 10010

Phone: 212.994.8250

Email: webmaster@minktherapeutics.com

Terms and Conditions Privacy Policy Cookie Policy © Copyright 2022. All Rights Reserved.